Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Rolapitant Is a Reversible Inhibitor of CYP2D6.

Glass SM, Leddy SM, Orwin MC, Miller GP, Furge KA, Furge LL.

Drug Metab Dispos. 2019 Jun;47(6):567-573. doi: 10.1124/dmd.118.085928. Epub 2019 Apr 5.

PMID:
30952677
2.

Disruption of tubular Flcn expression as a mouse model for renal tumor induction.

Chen J, Huang D, Rubera I, Futami K, Wang P, Zickert P, Khoo SK, Dykema K, Zhao P, Petillo D, Cao B, Zhang Z, Si S, Schoen SR, Yang XJ, Zhou M, Xiao GQ, Wu G, Nordenskjöld M, Tauc M, Williams BO, Furge KA, Teh BT.

Kidney Int. 2015 Nov;88(5):1057-69. doi: 10.1038/ki.2015.177. Epub 2015 Jun 17.

PMID:
26083655
3.

Pharmacologic inhibition of MEK signaling prevents growth of canine hemangiosarcoma.

Andersen NJ, Nickoloff BJ, Dykema KJ, Boguslawski EA, Krivochenitser RI, Froman RE, Dawes MJ, Baker LH, Thomas DG, Kamstock DA, Kitchell BE, Furge KA, Duesbery NS.

Mol Cancer Ther. 2013 Sep;12(9):1701-14. doi: 10.1158/1535-7163.MCT-12-0893. Epub 2013 Jun 26.

4.

CUL3 and NRF2 mutations confer an NRF2 activation phenotype in a sporadic form of papillary renal cell carcinoma.

Ooi A, Dykema K, Ansari A, Petillo D, Snider J, Kahnoski R, Anema J, Craig D, Carpten J, Teh BT, Furge KA.

Cancer Res. 2013 Apr 1;73(7):2044-51. doi: 10.1158/0008-5472.CAN-12-3227. Epub 2013 Jan 30.

5.

Evaluation of sex-specific gene expression in archived dried blood spots (DBS).

Resau JH, Ho NT, Dykema K, Faber MS, Busik JV, Nickolov RZ, Furge KA, Paneth N, Jewell S, Khoo SK.

Int J Mol Sci. 2012;13(8):9599-608. doi: 10.3390/ijms13089599. Epub 2012 Aug 2.

6.
7.

Expression of the PTTG1 oncogene is associated with aggressive clear cell renal cell carcinoma.

Wondergem B, Zhang Z, Huang D, Ong CK, Koeman J, Hof DV, Petillo D, Ooi A, Anema J, Lane B, Kahnoski RJ, Furge KA, Teh BT.

Cancer Res. 2012 Sep 1;72(17):4361-71. doi: 10.1158/0008-5472.CAN-11-2330. Epub 2012 Jul 17.

8.

Fumarate hydratase inactivation in renal tumors: HIF1α, NRF2, and "cryptic targets" of transcription factors.

Ooi A, Furge KA.

Chin J Cancer. 2012 Sep;31(9):413-20. doi: 10.5732/cjc.012.10102. Epub 2012 Jul 2. Review.

9.

Cancer-type regulation of MIG-6 expression by inhibitors of methylation and histone deacetylation.

Zhang YW, Staal B, Dykema KJ, Furge KA, Vande Woude GF.

PLoS One. 2012;7(6):e38955. doi: 10.1371/journal.pone.0038955. Epub 2012 Jun 12.

10.

An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma.

Ooi A, Wong JC, Petillo D, Roossien D, Perrier-Trudova V, Whitten D, Min BW, Tan MH, Zhang Z, Yang XJ, Zhou M, Gardie B, Molinié V, Richard S, Tan PH, Teh BT, Furge KA.

Cancer Cell. 2011 Oct 18;20(4):511-23. doi: 10.1016/j.ccr.2011.08.024.

11.

Identification of a lysosomal pathway that modulates glucocorticoid signaling and the inflammatory response.

He Y, Xu Y, Zhang C, Gao X, Dykema KJ, Martin KR, Ke J, Hudson EA, Khoo SK, Resau JH, Alberts AS, MacKeigan JP, Furge KA, Xu HE.

Sci Signal. 2011 Jul 5;4(180):ra44. doi: 10.1126/scisignal.2001450.

12.

Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets.

Ding Y, Huang D, Zhang Z, Smith J, Petillo D, Looyenga BD, Feenstra K, Mackeigan JP, Furge KA, Teh BT.

Cancer Res. 2011 Aug 1;71(15):5225-34. doi: 10.1158/0008-5472.CAN-11-0076. Epub 2011 Jun 3.

13.

MEK2 is sufficient but not necessary for proliferation and anchorage-independent growth of SK-MEL-28 melanoma cells.

Lee CS, Dykema KJ, Hawkins DM, Cherba DM, Webb CP, Furge KA, Duesbery NS.

PLoS One. 2011 Feb 18;6(2):e17165. doi: 10.1371/journal.pone.0017165.

14.

Deregulation of E2-EPF ubiquitin carrier protein in papillary renal cell carcinoma.

Roos FC, Evans AJ, Brenner W, Wondergem B, Klomp J, Heir P, Roche O, Thomas C, Schimmel H, Furge KA, Teh BT, Thüroff JW, Hampel C, Ohh M.

Am J Pathol. 2011 Feb;178(2):853-60. doi: 10.1016/j.ajpath.2010.10.033.

15.

MK-STYX, a catalytically inactive phosphatase regulating mitochondrially dependent apoptosis.

Niemi NM, Lanning NJ, Klomp JA, Tait SW, Xu Y, Dykema KJ, Murphy LO, Gaither LA, Xu HE, Furge KA, Green DR, MacKeigan JP.

Mol Cell Biol. 2011 Apr;31(7):1357-68. doi: 10.1128/MCB.00788-10. Epub 2011 Jan 24.

16.

Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas.

Looyenga BD, Furge KA, Dykema KJ, Koeman J, Swiatek PJ, Giordano TJ, West AB, Resau JH, Teh BT, MacKeigan JP.

Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1439-44. doi: 10.1073/pnas.1012500108. Epub 2011 Jan 10.

17.

Birt-Hogg-Dubé renal tumors are genetically distinct from other renal neoplasias and are associated with up-regulation of mitochondrial gene expression.

Klomp JA, Petillo D, Niemi NM, Dykema KJ, Chen J, Yang XJ, Sääf A, Zickert P, Aly M, Bergerheim U, Nordenskjöld M, Gad S, Giraud S, Denoux Y, Yonneau L, Méjean A, Vasiliu V, Richard S, MacKeigan JP, Teh BT, Furge KA.

BMC Med Genomics. 2010 Dec 16;3:59. doi: 10.1186/1755-8794-3-59.

18.

Comparative gene expression profiling analysis of urothelial carcinoma of the renal pelvis and bladder.

Zhang Z, Furge KA, Yang XJ, Teh BT, Hansel DE.

BMC Med Genomics. 2010 Dec 15;3:58. doi: 10.1186/1755-8794-3-58.

19.

Genetic and structural variation in the gastric cancer kinome revealed through targeted deep sequencing.

Zang ZJ, Ong CK, Cutcutache I, Yu W, Zhang SL, Huang D, Ler LD, Dykema K, Gan A, Tao J, Lim S, Liu Y, Futreal PA, Grabsch H, Furge KA, Goh LK, Rozen S, Teh BT, Tan P.

Cancer Res. 2011 Jan 1;71(1):29-39. doi: 10.1158/0008-5472.CAN-10-1749. Epub 2010 Nov 19.

20.

Genomic expression and single-nucleotide polymorphism profiling discriminates chromophobe renal cell carcinoma and oncocytoma.

Tan MH, Wong CF, Tan HL, Yang XJ, Ditlev J, Matsuda D, Khoo SK, Sugimura J, Fujioka T, Furge KA, Kort E, Giraud S, Ferlicot S, Vielh P, Amsellem-Ouazana D, Debré B, Flam T, Thiounn N, Zerbib M, Benoît G, Droupy S, Molinié V, Vieillefond A, Tan PH, Richard S, Teh BT.

BMC Cancer. 2010 May 12;10:196. doi: 10.1186/1471-2407-10-196.

21.

Kinase targets in renal-cell carcinomas: reassessing the old and discovering the new.

Furge KA, MacKeigan JP, Teh BT.

Lancet Oncol. 2010 Jun;11(6):571-8. doi: 10.1016/S1470-2045(09)70380-8. Epub 2010 Apr 8. Review.

PMID:
20381423
22.

Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma.

Huang D, Ding Y, Zhou M, Rini BI, Petillo D, Qian CN, Kahnoski R, Futreal PA, Furge KA, Teh BT.

Cancer Res. 2010 Feb 1;70(3):1063-71. doi: 10.1158/0008-5472.CAN-09-3965. Epub 2010 Jan 26.

23.

Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomerase-inhibiting therapy.

Schaeffer EM, Guzzo TJ, Furge KA, Netto G, Westphal M, Dykema K, Yang X, Zhou M, Teh BT, Pavlovich CP.

BJU Int. 2010 Jul;106(1):62-5. doi: 10.1111/j.1464-410X.2009.09139.x. Epub 2009 Dec 11.

24.

Activation of the PI3K/AKT pathway induces urothelial carcinoma of the renal pelvis: identification in human tumors and confirmation in animal models.

Qian CN, Furge KA, Knol J, Huang D, Chen J, Dykema KJ, Kort EJ, Massie A, Khoo SK, Vanden Beldt K, Resau JH, Anema J, Kahnoski RJ, Morreau H, Camparo P, Comperat E, Sibony M, Denoux Y, Molinie V, Vieillefond A, Eng C, Williams BO, Teh BT.

Cancer Res. 2009 Nov 1;69(21):8256-64. doi: 10.1158/0008-5472.CAN-09-1689. Epub 2009 Oct 20.

25.

5q- myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics.

Eisenmann KM, Dykema KJ, Matheson SF, Kent NF, DeWard AD, West RA, Tibes R, Furge KA, Alberts AS.

Oncogene. 2009 Oct 1;28(39):3429-41. doi: 10.1038/onc.2009.207. Epub 2009 Jul 13. Review.

PMID:
19597464
26.

Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer.

Graveel CR, DeGroot JD, Su Y, Koeman J, Dykema K, Leung S, Snider J, Davies SR, Swiatek PJ, Cottingham S, Watson MA, Ellis MJ, Sigler RE, Furge KA, Vande Woude GF.

Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12909-14. doi: 10.1073/pnas.0810403106. Epub 2009 Jun 30.

27.

MicroRNA profiling of human kidney cancer subtypes.

Petillo D, Kort EJ, Anema J, Furge KA, Yang XJ, Teh BT.

Int J Oncol. 2009 Jul;35(1):109-14.

PMID:
19513557
28.

The Wnt co-receptor Lrp6 is required for normal mouse mammary gland development.

Lindvall C, Zylstra CR, Evans N, West RA, Dykema K, Furge KA, Williams BO.

PLoS One. 2009 Jun 5;4(6):e5813. doi: 10.1371/journal.pone.0005813.

29.

Regulation of endocytosis via the oxygen-sensing pathway.

Wang Y, Roche O, Yan MS, Finak G, Evans AJ, Metcalf JL, Hast BE, Hanna SC, Wondergem B, Furge KA, Irwin MS, Kim WY, Teh BT, Grinstein S, Park M, Marsden PA, Ohh M.

Nat Med. 2009 Mar;15(3):319-24. doi: 10.1038/nm.1922. Epub 2009 Mar 1.

PMID:
19252501
30.

A comparison study reveals important features of agreement and disagreement between summarized DNA and RNA data obtained from renal cell carcinoma.

Zhang ZF, Matsuda D, Khoo SK, Buzzitta K, Block E, Petillo D, Richard S, Anema J, Furge KA, Teh BT.

Mutat Res. 2008 Nov 17;657(1):77-83. doi: 10.1016/j.mrgentox.2008.08.009. Epub 2008 Aug 23.

PMID:
18790077
31.

Somatic pairing of chromosome 19 in renal oncocytoma is associated with deregulated EGLN2-mediated [corrected] oxygen-sensing response.

Koeman JM, Russell RC, Tan MH, Petillo D, Westphal M, Koelzer K, Metcalf JL, Zhang Z, Matsuda D, Dykema KJ, Houseman HL, Kort EJ, Furge LL, Kahnoski RJ, Richard S, Vieillefond A, Swiatek PJ, Teh BT, Ohh M, Furge KA.

PLoS Genet. 2008 Sep 5;4(9):e1000176. doi: 10.1371/journal.pgen.1000176. Erratum in: PLoS Genet. 2008 Jul;4(7). doi: 10.1371/annotation/7f57058f-cc02-45a6-bfab-a835619e3916.

32.

Combining differential expression, chromosomal and pathway analyses for the molecular characterization of renal cell carcinoma.

Furge KA, Dykema K, Petillo D, Westphal M, Zhang Z, Kort EJ, Teh BT.

Can Urol Assoc J. 2007 Jun;1(2 Suppl):S21-7.

33.

The E2F3-Oncomir-1 axis is activated in Wilms' tumor.

Kort EJ, Farber L, Tretiakova M, Petillo D, Furge KA, Yang XJ, Cornelius A, Teh BT.

Cancer Res. 2008 Jun 1;68(11):4034-8. doi: 10.1158/0008-5472.CAN-08-0592.

34.

Renal translocation carcinomas: clinicopathologic, immunohistochemical, and gene expression profiling analysis of 31 cases with a review of the literature.

Camparo P, Vasiliu V, Molinie V, Couturier J, Dykema KJ, Petillo D, Furge KA, Comperat EM, Lae M, Bouvier R, Boccon-Gibod L, Denoux Y, Ferlicot S, Forest E, Fromont G, Hintzy MC, Laghouati M, Sibony M, Tucker ML, Weber N, Teh BT, Vieillefond A.

Am J Surg Pathol. 2008 May;32(5):656-70. doi: 10.1097/PAS.0b013e3181609914.

PMID:
18344867
35.

Experimental approaches to microarray analysis of tumor samples.

Furge LL, Winter MB, Meyers JI, Furge KA.

Biochem Mol Biol Educ. 2008 Mar;36(2):149-52. doi: 10.1002/bmb.20161.

36.

Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma.

Furge KA, Chen J, Koeman J, Swiatek P, Dykema K, Lucin K, Kahnoski R, Yang XJ, Teh BT.

Cancer Res. 2007 Apr 1;67(7):3171-6.

37.

Identification of deregulated oncogenic pathways in renal cell carcinoma: an integrated oncogenomic approach based on gene expression profiling.

Furge KA, Tan MH, Dykema K, Kort E, Stadler W, Yao X, Zhou M, Teh BT.

Oncogene. 2007 Feb 26;26(9):1346-50. Review.

PMID:
17322920
38.

Gene expression profiling in kidney cancer: combining differential expression and chromosomal and pathway analyses.

Furge KA, Kort EJ, Yang XJ, Stadler WM, Kim H, Teh BT.

Clin Genitourin Cancer. 2006 Dec;5(3):227-31.

PMID:
17239277
39.

Array-based comparative genomic hybridization reveals recurrent chromosomal aberrations and Jab1 as a potential target for 8q gain in hepatocellular carcinoma.

Patil MA, Gütgemann I, Zhang J, Ho C, Cheung ST, Ginzinger D, Li R, Dykema KJ, So S, Fan ST, Kakar S, Furge KA, Büttner R, Chen X.

Carcinogenesis. 2005 Dec;26(12):2050-7. Epub 2005 Jul 6.

PMID:
16000397
40.

A molecular classification of papillary renal cell carcinoma.

Yang XJ, Tan MH, Kim HL, Ditlev JA, Betten MW, Png CE, Kort EJ, Futami K, Furge KA, Takahashi M, Kanayama HO, Tan PH, Teh BS, Luan C, Wang K, Pins M, Tretiakova M, Anema J, Kahnoski R, Nicol T, Stadler W, Vogelzang NG, Amato R, Seligson D, Figlin R, Belldegrun A, Rogers CG, Teh BT.

Cancer Res. 2005 Jul 1;65(13):5628-37.

42.

Gene expression profiling of renal cell carcinoma.

Tan MH, Rogers CG, Cooper JT, Ditlev JA, Maatman TJ, Yang X, Furge KA, Teh BT.

Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6315S-21S. Review.

43.
44.

Robust classification of renal cell carcinoma based on gene expression data and predicted cytogenetic profiles.

Furge KA, Lucas KA, Takahashi M, Sugimura J, Kort EJ, Kanayama HO, Kagawa S, Hoekstra P, Curry J, Yang XJ, Teh BT.

Cancer Res. 2004 Jun 15;64(12):4117-21.

45.

Gene expression profiling of early- and late-relapse nonseminomatous germ cell tumor and primitive neuroectodermal tumor of the testis.

Sugimura J, Foster RS, Cummings OW, Kort EJ, Takahashi M, Lavery TT, Furge KA, Einhorn LH, Teh BT.

Clin Cancer Res. 2004 Apr 1;10(7):2368-78.

46.

Molecular subclassification of kidney tumors and the discovery of new diagnostic markers.

Takahashi M, Yang XJ, Sugimura J, Backdahl J, Tretiakova M, Qian CN, Gray SG, Knapp R, Anema J, Kahnoski R, Nicol D, Vogelzang NJ, Furge KA, Kanayama H, Kagawa S, Teh BT.

Oncogene. 2003 Oct 2;22(43):6810-8.

PMID:
14555994
47.
48.

Gene expression profiling of favorable histology Wilms tumors and its correlation with clinical features.

Takahashi M, Yang XJ, Lavery TT, Furge KA, Williams BO, Tretiakova M, Montag A, Vogelzang NJ, Re GG, Garvin AJ, Söderhäll S, Kagawa S, Hazel-Martin D, Nordenskjold A, Teh BT.

Cancer Res. 2002 Nov 15;62(22):6598-605.

49.

CIT: identification of differentially expressed clusters of genes from microarray data.

Rhodes DR, Miller JC, Haab BB, Furge KA.

Bioinformatics. 2002 Jan;18(1):205-6.

PMID:
11836234
50.

Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase.

Furge KA, Kiewlich D, Le P, Vo MN, Faure M, Howlett AR, Lipson KE, Vande Woude GF, Webb CP.

Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10722-7. Epub 2001 Sep 4.

Supplemental Content

Loading ...
Support Center